Antiretroviral therapy coverage in Tunisia
Tunisia: Antiretroviral therapy coverage was 29.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Tunisia, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
In 2024, antiretroviral therapy coverage in Tunisia stood at 29.0%. That is the highest value across all 25 years on record.
The figure is up 7.4% on the previous year and up 141.7% over ten years.
Over the whole period, antiretroviral therapy coverage in Tunisia peaked at 29.0% in 2024 and was at its lowest, 0.0%, in 2000.
That places Tunisia 136th out of 143 countries with data for 2024, putting it in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Tunisia, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 2.0% | — |
| 2002 | 2.0% | +0.0% |
| 2003 | 3.0% | +50.0% |
| 2004 | 3.0% | +0.0% |
| 2005 | 4.0% | +33.3% |
| 2006 | 5.0% | +25.0% |
| 2007 | 6.0% | +20.0% |
| 2008 | 6.0% | +0.0% |
| 2009 | 8.0% | +33.3% |
| 2010 | 9.0% | +12.5% |
| 2011 | 10.0% | +11.1% |
| 2012 | 9.0% | -10.0% |
| 2013 | 10.0% | +11.1% |
| 2014 | 12.0% | +20.0% |
| 2015 | 13.0% | +8.3% |
| 2016 | 15.0% | +15.4% |
| 2017 | 15.0% | +0.0% |
| 2018 | 17.0% | +13.3% |
| 2019 | 20.0% | +17.6% |
| 2020 | 22.0% | +10.0% |
| 2021 | 23.0% | +4.5% |
| 2022 | 26.0% | +13.0% |
| 2023 | 27.0% | +3.8% |
| 2024 | 29.0% | +7.4% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 3.9% | 0.0% | 8.0% | 10 |
| 2010s | 13.0% | 9.0% | 20.0% | 10 |
| 2020s | 25.4% | 22.0% | 29.0% | 5 |
Countries ranked near Tunisia
- 134 Philippines 40.0% compare
- 135 Congo 34.0% compare
- 136 Madagascar 29.0% compare
- 136 Yemen 29.0% compare
- 139 Djibouti 25.0% compare
More health data for Tunisia
- Un projection of annual infant deaths, annual growth rate -1.68 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.2883 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,287 deaths per 1,000 people (2090)
- Number of infants who die before age 1 117 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -3.64 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.033 units per person (2025)
- Population ages 00-04, male, annual growth rate -3.77 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Tunisia?
- Antiretroviral therapy coverage in Tunisia was 29.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Tunisia?
- The highest recorded value was 29.0% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Tunisia?
- The lowest recorded value was 0.0% in 2000.
- How does Tunisia rank for antiretroviral therapy coverage?
- Tunisia ranks 136th out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Tunisia?
- Over the last ten years it is up 141.7%. The long-run trend across the full record is volatile.
- Where does this Tunisia data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.